Want to see GB:OPTI full AI Analyst Report?
OPTI Stock Chart & Stats
6.75 p
0.00 p(0.00%)
At close: 4:00 PM EST
6.75 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range4.50 p - 13.50 p
Previous CloseN/A
Volume20.25K
Average Volume (3M)268.80K
Market Cap
£6.61M
Enterprise Value5.11M
Total Cash (Recent Filing)£1.04M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding103,300,300
10 Day Avg. Volume266,472
30 Day Avg. Volume268,800
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)5.86
P/FCF Ratio-3.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Licensing ModelOptiBiotix’s core B2B licensing and ingredient-supply model creates scalable, low-capex revenue channels. Licensing enables royalty and fee income tied to partner sales, leveraging third-party distribution and brand reach for sustainable revenue without heavy in-house retail investment.
Revenue Growth & Margin ExpansionSharp 2025 revenue growth alongside a notable jump in gross margin signals improving product-market fit and better unit economics. If margins and topline growth persist, the company can realize operating leverage, making a structural path toward profitability more achievable as partnerships scale.
Debt-light Balance SheetA lack of reported debt reduces refinancing and interest-rate risk, preserving financial flexibility. This debt-light position gives the company optionality to raise targeted capital, invest in commercialization or R&D, and absorb near-term volatility without material interest burdens.
Bears Say
Persistent Cash BurnSustained negative operating cash flow requires ongoing external funding, increasing dilution or refinancing needs. Persistent cash burn constrains investment in commercialization and R&D, shortens runway absent partner-generated royalties, and represents a clear medium-term liquidity risk for the business model.
Material UnprofitabilityWidening net and operating losses show costs are scaling faster than revenue, producing negative returns on equity. Until operating expenses are aligned with scalable revenue or higher-margin licensing income, profitability remains elusive and shareholder value is at risk from continued dilution.
Partner Dependence & Limited Internal ScaleHeavy reliance on third-party partners for product distribution, combined with a very small headcount, limits control over commercialization, timing and market execution. Undisclosed partner contributions increase revenue visibility risk and concentrate execution exposure outside the company’s direct control.
OptiBiotix Health News
OPTI FAQ
What was OptiBiotix Health PLC’s price range in the past 12 months?
OptiBiotix Health PLC lowest share price was 4.50 p and its highest was 13.50 p in the past 12 months.
What is OptiBiotix Health PLC’s market cap?
OptiBiotix Health PLC’s market cap is £6.61M.
When is OptiBiotix Health PLC’s upcoming earnings report date?
OptiBiotix Health PLC’s upcoming earnings report date is Sep 30, 2026 which is in 75 days.
How were OptiBiotix Health PLC’s earnings last quarter?
OptiBiotix Health PLC released its earnings results on May 28, 2026. The company reported -0.026 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.026 p.
Is OptiBiotix Health PLC overvalued?
According to Wall Street analysts OptiBiotix Health PLC’s price is currently Overvalued.
Does OptiBiotix Health PLC pay dividends?
OptiBiotix Health PLC does not currently pay dividends.
What is OptiBiotix Health PLC’s EPS estimate?
OptiBiotix Health PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OptiBiotix Health PLC have?
OptiBiotix Health PLC has 103,300,300 shares outstanding.
What happened to OptiBiotix Health PLC’s price movement after its last earnings report?
OptiBiotix Health PLC reported an EPS of -0.026 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.087%.
Which hedge fund is a major shareholder of OptiBiotix Health PLC?
Currently, no hedge funds are holding shares in GB:OPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OptiBiotix Health PLC
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and tailored blends intended for integration into food products, nutritional supplements, and active ingredients. Their groundbreaking work aims to positively influence human physiology and yield substantial health benefits. Among its diverse product portfolio are Slimbiome, a natural ingredient for healthy and satiety-driven weight management, and SlimBiome Medical, a supplemental aid for weight control. Other offerings include CholBiome, a dietary supplement for maintaining healthy cholesterol; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health and overall well-being; LPGOS, a galactooligosaccharide utilized in food applications to mitigate cardiovascular risk factors and enhance general health; WellBiome, a functional fiber and mineral blend designed to bolster gut microbiome diversity and promote wellness; and Sweetbiotix, a sweetener for use in various foods and beverages. Ultimately, OptiBiotix's innovations are designed to prevent and manage prevalent chronic lifestyle diseases, including obesity, high cholesterol, and diabetes. The company was founded in 2012.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
Nuformix Plc
―
Cizzle Biotechnology Holdings PLC
―
SkinBioTherapeutics
―